Source comparison
CJC-1295 No DAC vs Sermorelin: Research Application Comparison
Before selecting a peptide for a specific protocol, consider these functional trade-offs: Half-life 8–12 minutes ~30 minutes CJC-1295 no DAC provides 2.5–3× longer receptor occupancy, reducing dosing frequency but deviating from endogenous kinetics GH pulse du
This comparison does not assign a generated winner or score.
- Before selecting a peptide for a specific protocol, consider these functional trade-offs:
- Half-life
- 8–12 minutes
- ~30 minutes
- CJC-1295 no DAC provides 2.5–3× longer receptor occupancy, reducing dosing frequency but deviating from endogenous kinetics
- GH pulse duration
- 60–90 minutes above baseline
- 2–3 hours above baseline
- Sermorelin mimics natural pulse width; CJC-1295 no DAC models prolonged GHRH receptor activation
- Dosing frequency
- 2–3× daily
- 1–2× daily
- Sermorelin requires multiple doses to maintain pulse frequency throughout the day
- DPP-IV resistance
- No. Rapid degradation
- Yes. D-amino acid substitutions block cleavage
- CJC-1295 no DAC's structural modifications are the sole reason for kinetic difference
- Synergy with GHRPs
- High peak, short duration
- High peak, extended duration
- Both produce synergistic GH release; duration trade-off depends on research objective
- Physiological fidelity
- High. Replicates endogenous GHRH kinetics
- Moderate. Extends receptor activation beyond natural pattern
- Sermorelin better models natural GH secretion; CJC-1295 no DAC suits pharmacological intervention studies
- Reconstitution stability
- 28 days at 2–8°C
- Both require bacteriostatic water and refrigerated storage post-reconstitution